Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp (NQ: LEXX )

1.600 -0.030 (-1.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 200,484
Open 1.630
Bid (Size) 1.440 (1)
Ask (Size) 1.780 (3)
Prev. Close 1.630
Today's Range 1.420 - 1.700
52wk Range 0.6488 - 3.595
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Tech Lowers Blood Glucose More Effectively than Branded GLP-1 drug Semaglutide Alone, Study Shows
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Tech Lowers Blood Glucose More Effectively than Branded GLP-1 drug Semaglutide Alone, Study Shows
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property

Performance

YTD
-37.25%
-37.25%
1 Month
+20.30%
+20.30%
3 Month
+55.34%
+55.34%
6 Month
+118.88%
+118.88%
1 Year
-34.43%
-34.43%

More News

Read More
Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Improve Oral Performance of GLP-1 Drug in Human Pilot Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Improve Oral Performance of GLP-1 Drug in Human Pilot Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Generate Sizable License Revenue from IP Growth, Expanding Patent Suite
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Advance Patented DehydraTECH(TM)
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Advance Patented DehydraTECH(TM)
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes $200 Billion GLP-1 Market with its DehydraTECH(TM) Technology
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes $200 Billion GLP-1 Market with its DehydraTECH(TM) Technology
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Exploring Patented DehydraTECH(TM) Technology’s Effectiveness on GLP-1 Drugs for Potential Diabetes Treatment and Weight Loss
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed CBD Proven Superior in Research
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Impact of Exclusive Drug-Delivery Solution on GLP-1 Drugs
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
Via Investor Brand Network
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
Via FinancialNewsMedia
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space
From Lexaria Bioscience Corp.
Via GlobeNewswire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows List of Licensed Partners Following Exclusive Collaboration and License Agreement with SulfoSyn
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
From Lexaria Bioscience Corp.
Via GlobeNewswire
Can Diabetes, Weight-Loss Drugs Get Even Better?
Via Investor Brand Network
Can Diabetes, Weight-Loss Drugs Get Even Better?
Via FinancialNewsMedia
Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Two New Canadian Patents Amid Continued Efforts to Safeguard the Applicability of Its DehydraTECH(TM) Technology in Multiple Jurisdictions and Sectors
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Raised $1.6 Million in Latest Investment Round; Looks to Advance DehydraTECH(TM) Research Operations
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Ongoing Diabetes Study Program to Examine its Patented DehydraTECH(TM) Technology with Launch of Human and Animal Studies for Oral GLP-1 Drugs
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback